Clarivate VIVO Sandbox

Academic Articles147

• (2020). Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review. CRITICAL CARE MEDICINE. 48(9), 1365-1374.

  
• (2020). Sepsis Bundles That Focus on Clinician Judgment and Proven Interventions Are Needed to Increase Bundle Compliance and Effectiveness. CRITICAL CARE MEDICINE. 48(4), 602-605.

  
• (2020). The Effects of Obesity on Outcome in Preclinical Animal Models of Infection and Sepsis: A Systematic Review and Meta-Analysis. Journal of Obesity. 2020,

  
• (2020). Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Medicine Experimental. 8(1),

  
• (2020). Driving blind: instituting SEP-1 without high quality outcomes data. Journal of Thoracic Disease. 12, S22-S36.

  
• (2019). Antibiotic- and Fluid-Focused Bundles Potentially Improve Sepsis Management, but High-Quality Evidence Is Lacking for the Specificity Required in the Centers for Medicare and Medicaid Service's Sepsis Bundle (SEP-1). CRITICAL CARE MEDICINE. 47(10), 1290-1300.

  
• (2019). Bacillus anthracis lethal toxin, but not edema toxin, increases pulmonary artery pressure and permeability in isolated perfused rat lungs. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 316(5), H1076-H1090.

  
• (2019). Does Obesity Protect Against Death in Sepsis? A Retrospective Cohort Study of 55,038 Adult Patients. CRITICAL CARE MEDICINE. 47(5), 643-650.

  
• (2018). Endorsing performance measures is a matter of trust. BMJ-British Medical Journal. 360,

  
• (2018). Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1) A Systematic Review. ANNALS OF INTERNAL MEDICINE. 168(8), 558-+.

  
• (2018). Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1) RESPONSE. ANNALS OF INTERNAL MEDICINE. 168(8), 610-612.

  
• (2018). Risks of restrictive red blood cell transfusion strategies in patients with cardiovascular disease (CVD): a meta-analysis. TRANSFUSION MEDICINE. 28(5), 335-345.

  
• (2017). A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B-anthracis infection: A need for more robust study designs and results. PLoS One. 12(8),

  
• (2017). Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009-2010. EMERGING INFECTIOUS DISEASES. 23(1), 56-65.

  
• (2017). Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support. Intensive Care Medicine Experimental. 5,

  
• (2017). Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model. INFECTION AND IMMUNITY. 85(7),

  
• (2017). Shock and lethality with anthrax edema toxin in rats are associated with reduced arterial responsiveness to phenylephrine and are reversed with adefovir. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 313(5), H946-H958.

  
• (2017). The Potential Pathogenic Contributions of Endothelial Barrier and Arterial Contractile Dysfunction to Shock Due to B-anthracis Lethal and Edema Toxins. Toxins. 9(12),

  
• (2016). Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis. CRITICAL CARE. 20,

  
• (2016). Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 311(3), H781-H793.

  
• (2015). An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 24(7), 851-865.

  
• (2015). Bacillus anthracis edema but not lethal toxin challenge in rats is associated with depressed myocardial function in hearts isolated and tested in a Langendorff system. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 308(12), H1592-H1602.

  
• (2015). Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies. Toxins. 7(12), 5417-5434.

  
• (2014). Confirmed Bacillus anthracis Infection among Persons Who Inject Drugs, Scotland, 2009-2010. EMERGING INFECTIOUS DISEASES. 20(9), 1452-1463.

  
• (2014). Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 307(11), E994-E1008.

  
• (2014). Purified cell wall from the probiotic bacterium Lactobacillus gasseri activates systemic inflammation and, at higher doses, produces lethality in a rat model. CRITICAL CARE. 18(4),

  
• (2014). Tidal Volume and Plateau Pressure Use for Acute Lung Injury From 2000 to Present: A Systematic Literature Review. CRITICAL CARE MEDICINE. 42(10), 2278-2289.

  
• (2013). Antitumor Necrosis Factor Therapy Is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis. CRITICAL CARE MEDICINE. 41(10), 2419-2429.

  
• (2013). B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components. BMC Medicine. 11,

  
• (2013). B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 305(2), H238-H250.

  
• (2013). Bacillus anthracis Cell Wall Peptidoglycan but Not Lethal or Edema Toxins Produces Changes Consistent With Disseminated Intravascular Coagulation in a Rat Model. JOURNAL OF INFECTIOUS DISEASES. 208(6), 978-989.

  
• (2013). The Surviving Sepsis Campaign's Revised Sepsis Bundles. Current Infectious Disease Reports. 15(5), 385-393.

  
• (2012). An overview of anthrax infection including the recently identified form of disease in injection drug users. INTENSIVE CARE MEDICINE. 38(7), 1092-1104.

  
• (2012). Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia. INTENSIVE CARE MEDICINE. 38(12), 2063-2071.

  
• (2012). Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock. CRITICAL CARE MEDICINE. 40(1), 199-207.

  
• (2012). Protective Antigen Antibody Augments Hemodynamic Support in Anthrax Lethal Toxin Shock in Canines. JOURNAL OF INFECTIOUS DISEASES. 205(5), 818-829.

  
• (2011). Anthrax Infection. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 184(12), 1333-1341.

  
• (2011). Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 300(3), H1108-H1118.

  
• (2011). Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice. CRITICAL CARE MEDICINE. 39(6), 1439-1447.

  
• (2011). Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opinion on Drug Metabolism & Toxicology. 7(4), 479-494.

  
• (2011). The Potential Contributions of Lethal and Edema Toxins to the Pathogenesis of Anthrax Associated Shock. Toxins. 3(9), 1185-1202.

  
• (2011). The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. CRITICAL CARE MEDICINE. 39(5), 1104-1112.

  
• (2011). The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 20(11), 1555-1564.

  
• (2011). The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model. INTENSIVE CARE MEDICINE. 37(10), 1688-1695.

  
• (2010). Anthrax Lethal and Edema Toxins Produce Different Patterns of Cardiovascular and Renal Dysfunction and Synergistically Decrease Survival in Canines. JOURNAL OF INFECTIOUS DISEASES. 202(12), 1885-1896.

  
• (2010). Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. INTENSIVE CARE MEDICINE. 36(1), 148-156.

  
• (2010). Bundled care for septic shock: An analysis of clinical trials. CRITICAL CARE MEDICINE. 38(2), 668-678.

  
• (2010). Evaluating guidelines for critical care: a need for detail. INTENSIVE CARE MEDICINE. 36(10), 1631-1632.

  
• (2010). Practice Misalignments in Randomized Controlled Trials: Identification, Impact, and Potential Solutions. ANESTHESIA AND ANALGESIA. 111(2), 444-450.

  
• (2010). Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis. CRITICAL CARE MEDICINE. 38(1), 306-308.